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Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, with mortality rates in excess
of 90%. We sought to identify a subgroup of patients less likely to beneﬁt from initial therapy with corticosteroids as well as the
impactofresponseonday14onoutcome.Retrospectiveevaluationwasperformedofpatientswithbiopsy-provenaGVHDtreated
with corticosteroids after allogeneic HSCT at M.D. Anderson Cancer Center from 1998 through 2002 (N = 287). Overall response
to ﬁrst-line therapy on day 14 was 56%. Grade III-IV aGVHD and hyperacute GVHD were the most signiﬁcant factors predicting
failure. Patients who fail to respond to steroids by day 14 should be considered for clinical trials. Severity of aGVHD, hyperacute
GVHD, and sex mismatch could be integrated into prognostic scoring systems which may allow for pretreatment identiﬁcation of
patients unlikely to beneﬁt from standard therapy with corticosteroids.
1.Introduction
Acute graft-versus-host disease (aGVHD) remains one of the
major limiting factors in successful allogeneic hematopoietic
stem cell transplantation (HSCT) [1, 2]. Standard treatment
for aGVHD consists of corticosteroids, although there is a
lack of consensus over optimal dosing and schedule [3]. Re-
sponse to corticosteroids is seen in approximately 50% of pa-
tients [2], and those who fail initial therapy have mortality
r a t e sa sh i g ha s9 5 %[ 4].
Response to ﬁrst-line therapy as a predictor of outcome
has been systematically assessed in multiple recent studies
[5–7]whichconcurredthatbothday14andday28responses
were highly correlated with outcome and each other. How-
ever, day 28 response was the strongest predictor statistical-
ly. These ﬁndings are in line with a consensus statement en-
dorsing day 28 response as the optimal endpoint in aGVHD
treatment trials [3].
There are currently no established prognostic models or
biomarkers to assist in the identiﬁcation of patients at high
risk offailing ﬁrst-linetherapy. Wehavepreviouslydescribed
thehyperacutepresentation,deﬁnedasthatoccurringwithin
14 days after transplantation irrespective of engraftment, as
associated with inferior response rate and survival outcomes
[8]. In the current study, we systematically evaluate patient,
transplant, and aGVHD characteristics as predictors for
failure to respond to initial therapy with corticosteroids in
a large patient population treated with standard ﬁrst-line
therapy. We speciﬁcally evaluated the eﬀect of these risk
factors on response to initial therapy with corticosteroids on
day 14 and the impact of response on nonrelapse mortality
(NRM).
2.MaterialsandMethods
2.1. Patients. We studied all consecutive patients who under-
went an allogeneic HSCT as part of prospective clinical
trials at the University of Texas M.D. Anderson Cancer
Center between January 1998 and September 2002. Patients
who received umbilical cord blood transplantation or T-cell
depleted graft were excluded from this study. HLA typing
was intermediate resolution for Class I antigens (HLA-A2 Advances in Hematology
and B) until 2001 (high resolution thereafter for matched
unrelated donor grafts) and high-resolution for HLA-DRB1.
Ifapatientreceivedmorethanoneallogeneictransplantdur-
ing the study period, only the initial transplant was utilized
for the statistical analysis, and further data was censored at
the time of subsequent transplantation. Patients who had
primary graft failure were not eligible for inclusion in the
study.
All patients were treated on Institutional Review Board
approved research protocols at the M.D. Anderson Cancer
Center. Patients signed informed consent in accordance with
the Declaration of Helsinki. Demographic and clinical data
were retrieved from the Department of Stem Cell Trans-
plantationandCellularTherapyelectronicdatabase,whichis
prospectively updated according to standardized data entry
criteria and from the electronic medical records. A retro-
spective chart review protocol was approved by the institu-
tional IRB for the current analysis.
2.2. Conditioning Regimens and GVHD Prophylaxis. Condi-
tioning regimens are listed in Table 1. Myeloablative regi-
mens were expected to result in profound pancytopenia for
greater than 28 days, and hematopoietic recovery was com-
pletely donor-derived. Reduced-intensity regimens were de-
ﬁned as those in which recipient hematopoietic recovery was
expected to occur within 28 days without transplantation
and, after transplantation, chimerism could be documented
in most patients [9, 10].
2.3. Engraftment. Date of engraftment was deﬁned as the
ﬁrst of 3 consecutive days in which the patient had an abso-
lute neutrophil count of 0.5 ×109/L or greater. Failure to en-
graft by day 30 was considered primary graft failure. Sec-
ondarygraftfailureisdeﬁnedasfailuretosustainanabsolute
neutrophil count 0.5 × 109/L or greater after attainment of
primary engraftment.
2.4. Assessment of aGVHD. Diagnosis of aGVHD involved
clinical features, positive biopsy results from at least one
involved organ, and exclusion of other causes of rash, diar-
rhea, and liver function abnormalities. Patients without bio-
psy-provenGVHDwereexcludedfromtheanalysis(n = 55).
The staging and grading of aGVHD were performed using
the modiﬁed Glucksberg consensus criteria and occurred at
the time of initiation of treatment [11]. We deﬁned hypera-
cute GVHD as aGVHD occurring within the ﬁrst 14 days
after HSCT as previously published [8]. Mild-to-moderate
aGVHD includes patients with grade I and II disease, while
grades III and IV were considered severe.
2.5. Evaluation of Response to Therapy. Each organ system
was prospectively and retrospectively assessed for response
to therapy. Complete responses (CR) and partial responses
(PR) were assessed 14 days after the initiation of therapy [2].
A CR was deﬁned as the complete resolution of all manifes-
tations of aGVHD. A PR was a decrease in organ stage by
1. Progressive disease (PD) was deﬁned as an increase in
organ stage by 1 and was evaluated 48 hours (gastrointestinal
(GI) and liver) or 72 hours (skin) after the initiation
Table 1: Patients and transplant characteristics.
Characteristic Value (%)
No. of patients 287
Patient age
Median, y (range) 45 (19–72)
Older than 40 y 138 (48)
40 y or younger 149 (52)
Median no. of prior chemotherapy lines (range) 2 (0–9)
Donor/patient sex mismatch
Female Donor/Male Patient 73 (25)
Other 214 (75)
Diagnosis
Lymphoid 163 (57)
Myeloid 100 (35)
Multiple myeloma 8 (3)
Solid tumor 4 (1)
Other 12 (4)
Disease status at transplantation
Not in remission 188 (66)
Remission 99 (34)
Donor type
Matched 251 (88)
Mismatched 36 (12)
Cell source
Peripheral Blood 126 (44)
Bone Marrow 161 (56)
Conditioning regimen
Reduced intensity 102 (35.5)
High-dose chemotherapy 137 (50.5)
High-dose chemotherapy/TBI 48 (13.9)
of corticosteroids. Patients were considered nonresponders
(NRs) in the absence of CR, PR, or PD 7 days after the ini-
tiation of corticosteroids for skin GVHD or 72 hours after
its initiation for GI and liver GVHD. Overall response inte-
grated the responses at all sites (skin, GI, and liver). An over-
allCRwasdeﬁnedastheresolutionofGVHDinallevaluable
organs for a minimum duration of 14 days. Overall PR was
any improvement in at least one evaluable organ without de-
terioration of others. Overall PD was deterioration in at least
one evaluable organ without improvement of the others. NR
was the absence of any change or any situation other than
CR, PR, or PD. Thus, steroid refractory patients were those
in the NR and PD categories.
2.6. Statistical Methods. Analysis was performed on the
basis of outcomes documented by July 2007. Patients who
experienced secondary graft failure after neutrophil engraft-
ment were censored at the time of the secondary graft fail-
ure. Predictors of response to ﬁrst line therapy in patients
diagnosedwithgradeI–IVaGVHDwereassessedonunivari-
ate and multivariate analysis using logistic regression anal-
ysis. Factors evaluated included grade of aGVHD at the
time of initiation of systemic therapy, time of onset ofAdvances in Hematology 3
aGVHD, patient age, donor/patient gender, donor type, cell
type, intensity of conditioning regimen, underlying malig-
nancy, disease status at transplantation, number of prior
chemotherapy regimens received, infused dose of CD34+
cells, and the steroid dose at the initiation of systemic ther-
apy. Predictors of NRM were assessed on univariate and
multivariateanalysisusingCox’sproportionalhazardsmodel
[12]. The cumulative incidence of NRM and chronic GVHD
were estimated by the cumulative incidence method [13]
considering death due to persistence or recurrence of under-
lying malignancy and death before the development of
chronic GVHD as competing risks, respectively. Actuarial
survival was estimated by the Kaplan-Meier method. All out-
comeswereestimatedsincetheinitiationofﬁrst-linetherapy.
Factors signiﬁcant at the 0.1 level on univariate analysis were
considered for multivariate analyses using backward elim-
ination. Two-sided P values less than .05 were considered
signiﬁcant. Analysis was performed using STATA 7.0 (Stata,
College Station, TX).
3. Results
3.1. Demographics and Incidence of Acute GVHD. At o t a l
of 818 patients received allogeneic HSCT transplantation
during the study period including 287 who met the inclusion
criteria for the current analysis. Patient characteristics are
listed in Table 1. Of the 287 patients, 198 (69%) developed
grade II–IV aGVHD. Nearly all patients received tacrolimus
(98%, n = 283) or tacrolimus and methotrexate (n = 276,
96%) starting on day −2, targeting blood levels of 5–15ng/
dL. Patients were started on methylprednisolone at 2mg/kg
daily at the time of onset of aGVHD. A subset of patients
with grade I-II aGVHD received less than 2mg/kg of daily
methylprednisolone (n = 24, median 1mg/kg, range 0.3–
1.5mg/kg) as initial therapy. Pentostatin (n = 10, 3%) or
corticosteroids (n = 3, 1%) were added to the GVHD
prophylaxis regimen as part of studies involving unrelated
donor or HLA-mismatched transplants, and antithymocyte
globulin was given as part of the conditioning regimen in 79
(29.6%) patients.
Seventy-six patients (26%) developed aGVHD prior to
day 14 and were categorized as hyperacute GVHD, of which
13 were categorized as severe. Seventy-three patients (25%)
were sex mismatched (female donor and male recipient),
with 16 categorized as severe. In about half of the patients
(n = 132, 46%), skin was the only organ involved.
3.2.FrontlineTreatmentofaGVHD. PatientswithgradeI–IV
aGVHD were started on methylprednisolone (MP) accord-
ing to institutional guidelines (Table 2). Tacrolimus was con-
tinued at blood levels between 5 and 15ng/dL. A total of 27
patients (9%) received one or more additional immunosup-
pressantsforfrontlinetreatmentofaGVHD,includinginﬂix-
imab (n = 17, 6%), daclizumab (n = 5, 2%), pentostatin
(n = 3, 1%), and basiliximab (n = 4, 1%).
3.3. Response to First-Line Therapy for Acute GVHD. Of the
287 patients, 161 (56%) achieved a CR or PR at two weeks
after the initiation of ﬁrst line therapy (Table 2). Time to
developmentofaGVHDwasassessedbyquartiles,andday14
corresponded to the 25th percentile of the distribution our
study population. The majority of patients who failed ﬁrst-
line corticosteroids were subsequently treated on protocols
with various investigational agents.
On univariate analysis, overall grade of aGVHD at the
time of initiation of systemic therapy was the strongest
predictor of response (CR or PR). A signiﬁcantly higher pro-
portionofpatientswithmild-to-moderateaGVHDrespond-
ed to ﬁrst-line therapy than those with severe aGVHD (60%
versus 39%, P = 0.003). The proportion of responders was
similar in patients with grade I (65%) and II (57%) aGVHD
(P = 0.2) in the mild-to-moderate group, and in those
with grade III (39%) and IV (33%) aGVHD (P = 0.7) in
the severe group. Response was also signiﬁcantly lower for
patients who were diagnosed with hyperacute GVHD com-
pared with those whose aGVHD was diagnosed later (42%
versus 61%, P = 0.007). The lower response rate for patients
with hyperacute GVHD was seen in patients with mild-to-
moderate aGVHD (48% versus 65%, P = 0.03) as well as
those severe aGVHD (15% versus 45%, P = 0.05). Converse-
ly, sex mismatch (female donor and male recipient) was
associated with signiﬁcantly lower response in patients with
grade III-IV (CR/PR 12% versus 49%, P = 0.01) but not in
patients with grade I-II (CR/PR 61% versus 60%, P = 0.9).
There was also a trend for higher response in patients who
had active disease at transplant, and those who received a
g r a f t e df r o mam a t c h e dd o n o r .
Factorsthatweresigniﬁcant(P<0.05)ormarginallysig-
niﬁcant (P<0.1) on univariate analysis were assessed in
multivariate analysis including the severity of aGVHD at the
initiation of therapy (grade I-II versus grade III-IV), time
of onset of aGVHD (hyperacute versus other), donor type,
and disease status at the time of transplantation. Sex mis-
match in the severe aGVHD group was not considered in
multivariate analysis because the estimate was based on a
very small number of patients. Among these factors, only
severity and time of onset of aGVHD remained signiﬁcant
on multivariate analysis.
To quantify the independent eﬀects of severity and time
of onset of aGVHD, the multivariate model was construct-
ed based on four mutually exclusive groups of patients
depending on the severity and the time of onset of aGVHD
(Table 3). Patients who had mild-to-moderate aGVHD and
were diagnosed with aGVHD beyond day 14 from transplan-
tation (n = 170) had a signiﬁcantly higher response rate
(65%), followed in decreasing order of response by those
who had mild-to-moderate hyperacute aGVHD (n = 60,
48%,P = 0.03),severeaGVHDdiagnosedafterday+14(n =
44, 45%, P = 0.02), and severe hyperacute aGVHD (n = 13,
15%, P = 0.003). This grouping of patients will be used
for further evaluation of the independent eﬀect of severi-
ty and time of onset of aGVHD on survival.
3.4. Overall Survival and Nonrelapse Mortality. The median
followup among survivors was 42 months (range 16–73).
Actuarial survival was 41% in responders and 22% in nonre-
sponders at 18 months (P<0.001), and 36% versus 17%
(P<0.001) at 2 years, respectively (Figure 1). Similarly,4 Advances in Hematology
Table 2: Evaluation of predicators of ﬁrst-line therapy for treatment of acute GVHD.
Predictor No. of patients CR/PR, no. of
patients
OR Univariate 95% CI P
G r a d ea tﬁ r s tl i n et h e r a p y
I 89 58 (65) Reference — —
II 141 81 (57) 0.7 0.4–1.2 0.2
III 54 21 (39) 0.3 0.2–0.7 0.003
IV 3 1 (33) 0.3 0.02–3.1 0.3
Grade III-IV 0.4 0.2–0.7 0.003
Age
≤45 (median) 138 74 (54) Reference — —
>45 149 87 (58) 1.2 0.8–1.9 0.4
Gender
F 112 60 (54) 0.8 0.5–1.4 0.5
M 175 101 (58) Reference — —
Donor/patient sex
Female/Male 73 37 (51) 0.7 0.4–1.3 0.3
Other 214 124 (58) Reference — —
Conditioning regimen
Total body irradiation 48 27 (56) 1.1 0.5–2.2 0.8
High Dose, No total body irradiation 137 90 (57) 1.1 0.6–1.9 0.7
Reduced intensity 102 44 (54) Reference
Allotype
Matched 251 146 (58) 1.9 0.96–3.9 0.06
Mismatched 36 15 (42) Reference — —
Cell type
BM 161 87 (54) 0.8 0.5–1.3 0.4
PB 126 74 (59) Reference — —
Diagnosis
Myeloid 163 90 (55) 0.6 0.2–2.0 0.4
Lymphoid 100 59 (59) Reference — —
Multiple myeloma 8 3 (37) Excluded — —
Other 4 4 (100) Excluded — —
Solid 12 5 (42) Excluded — —
Disease status at transplant
Active disease 188 113 (60) 1.6 0.98–2.6 0.06
No active disease 99 48 (48) Reference — —
Prior chemotherapy regimens
≤2 182 100 (55) Reference — —
>2 105 61 (58) 1.1 0.7–1.8 0.6
Dose of methylprednisolone ﬁrst line
<2mg 24 15 (62) Reference — —
2mg 250 144 (58) 0.8 0.3–1.9 0.6
Unknown 13 2 (15) Excluded
Days from transplant to aGVHD
≤14 73 31 (42) Reference — —
>14 214 130 (61) 0.5 0.3–0.8 0.007Advances in Hematology 5
Table 2: Continued.
Predictor No. of patients CR/PR, no. of
patients
OR Univariate 95% CI P
CD34 infused (quartile)
≤3.5 72 40 (56) Reference — —
>3.5 to ≤4.3 68 42 (62) 1.3 0.7–2.5 0.5
>4.3 to ≤5.5 73 40 (55) 0.97 0.5–1.9 0.9
>5.5 70 37 (37) 0.9 0.5–1.7 0.7
Table 3: Eﬀect of severity and time of onset of aGVHD on response.
Total no. of patients N = 287 (%) CR/PR, no. of patients (%) OR 95% CI P
Grade I-II and no Hyperacute GVHD 170 (59) 110 (65) Reference — —
Grade I-II and Hyperacute GVHD 60 (21) 29 (48) 0.5 0.3–0.9 0.03
Grade III-IV and no Hyperacute GVHD 44 (15) 20 (45) 0.4 0.2–0.9 0.02
Grade III-IV and Hyperacute GVHD 13 (5) 2 (15) 0.1 0.02–0.5 0.003
Figure 1: Overall survival in steroid responsive and refractory
aGVHD patients.
patients who failed to respond to ﬁrst-line therapy suﬀered
higher NRM at 18 months (63% versus 34%, P<0.001)
and 2 years (65% versus 35%, P<0.001) since initiation
of therapy. Causes of death according to response to ﬁrst
line therapy are presented in Table 4. Death was attributed
to aGVHD in 35% of cases in nonresponders versus 3% of
responders (P = 0.013). The rate of GVHD mortality (in-
cluding both acute and chronic) was signiﬁcantly lower in
the responding group (HR = 0.2, P<0.001).
3.5. Predictors of Nonrelapse Mortality. On univariate analy-
sis, failure to respond was the most signiﬁcant predictor of
NRM at two years after initiation of ﬁrst-line therapy (HR =
0.4, P<0.001). This eﬀect was consistent in patients with
mild-to-moderate (HR = 0.4, P<0.001) and those with
severe (HR = 0.4, P = 0.007) aGVHD. In addition, severe
aGVHD (HR = 2.2, P<0.001), the use of TBI in the con-
ditioning regimen (HR = 1.7, P = 0.025), and sex mismatch
(HR = 1.7, P = 0.003) were associated with a higher NRM
rate, whereas the use of a matched-related donor (HR = 0.6,
P = 0.004) and a lower dose of steroids at initiation of
Table 4: Primary cause of death among patients with aGVHD.
Causes of death
CR/PR Refractory
no. of deaths (%) no. of deaths (%)
115 109
Acute GVHD 4 (3) 38 (35)
Chronic GVHD 30 (26) 32 (29)
Disease persistence/recurrence 49 (43) 23 (21)
Infections 13 (11) 9 (8)
Other 15 (13) 6 (5)
Unknown 4 (3) 1 (1)
systemic therapy (<2mg/kg, HR = 0.4, P = 0.02) were
associated with a lower NRM rate. Hyperacute GVHD was
associated with a signiﬁcantly higher NRM in patients with
severe aGVHD (HR = 2.05, P = 0.04), but not in patients
with mild aGVHD (HR = 1.2, P = 0.4, Table 5). Covariates
consideredinmultivariateanalysisincludedresponsetoﬁrst-
line therapy, time of onset, and severity of aGVHD (severe
hyperacute aGVHD, and severe aGVHD diagnosed after day
14), the use of TBI in the conditioning regimen, the use of
a matched-related donor, and sex mismatch. Although the
dose of steroid was signiﬁcant on univariate analysis, it was
not considered in multivariate analysis because only one of
the 24 patients who received lower doses had severe aGVHD,
which precludes adjusting for confounding variables. Results
of the multivariate analysis were consistent with those
of the univariate analysis and conﬁrmed the independent
prognostic value of the response to ﬁrst-line therapy.
We performed additional subanalyses to further demon-
strate the independent eﬀect of response on NRM by group-
ing patients based on the severity, timing of onset, and
response of aGVHD (Table 6). Our data showed that
response to therapy was associated with more favorable out-
come in patients with mild-moderate aGVHD irrespective of
time of onset. Similarly it was associated with lower NRM
in patients with severe aGVHD diagnosed after day 14 after
transplant. We could not evaluate the impact of response in6 Advances in Hematology
Table 5: Univariate predictors of nonrelapse morality among patients with acute GVHD at 2 years.
Predictor N = 287 HR 95% CI P
Age (quartile)
≤35 69 Reference — —
>35 to ≤45 69 1 0.7–1.7 0.8
>45 to ≤55 83 0.9 0.6–1.5 0.8
>55 66 1.3 0.8–2.1 0.3
Dose of ﬁrst line
<2mg 24 0.4 0.2–0.9 0.02
2mg 250 Reference — —
Unknown 13 Reference — —
Response to ﬁrst line
CR/PR 161 0.4 0.3–0.5 <0.001
Other 126 Reference — —
Grade and hyper aGVHD
Grade I-II, no hyperacute GVHD 170 Reference — —
Grade I-II, hyperacute GVHD 60 1.2 0.8–1.9 0.4
Grade III-IV, no hyperacute GVHD 44 1.9 1.25–3.0 0.003
Grade III-IV, hyperacute GVHD 13 4.3 2.3–7.9 <0.001
Sex mismatch
Yes 73 1.7 1.2–2.4 0.003
No 214 Reference — —
Conditioning regimen
Total body irradiation 48 1.7 1.1–2.8 0.025
High dose, No total Body irradiation 158 0.97 0.6–1.4 0.9
Reduced intensity 81 Reference — —
Allotype
Matched-related 139 0.6 0.4–0.85 0.004
Matched unrelated 112 Reference — —
Antigen mismatch-related 36 Reference — —
Cell type
Bone marrow 161 1.1 0.8–1.6 0.5
Peripheral blood 126 Reference — —
Diagnosis
Myeloid 163 Reference — —
Lymphoid 100 0.9 0.7–1.4 0.9
Multiple myeloma 8 0.6 0.2–2 0.4
Other 4 0.6 0.1–2.5 0.5
Solid 12 0.6 0.2–1.7 0.3
Disease status at transplant
Active disease 188 1.1 0.8–1.5 0.7
No active disease 99 Reference — —
Prior chemotherapy regimens
≤2 182 Reference — —
>2 105 1.3 0.9–1.8 0.2
CD34 infused (10e6 cells, quartile)
≤3.5 72 Reference — —
>3.5 to ≤4.3 68 0.9 0.6–1.4 0.6
>4.3 to ≤5.5 73 0.7 0.5–1.2 0.2
>5.5 70 1.1 0.7–1.8 0.6Advances in Hematology 7
Table 6: The Eﬀect of severity, hyperacute GVHD, and response to corticosteroids on nonrelapse morality.
Hyperacute NRM at 100 days NRM at 1 year
Group Grade GVHD CR or PR N %C I H R P %C I H R P
1 1 or 2 No Yes 110 9% Reference — 27% Reference —
2 1 or 2 No No 60 23% 2.8 0.01 55% 2.5 <0.001
3 1 or 2 Yes Yes 29 3% 0.4 0.3 34% 1.1 0.7
4 1 or 2 Yes No 31 31% 4.9 <0.001 45% 2.5 0.003
5 3 or 4 No Yes 20 25% 2.9 0.05 35% 1.4 0.4
6 3 or 4 No No 24 50% 7.6 <0.001 75% 4.7 <0.001
7 3 or 4 Yes Yes 2 100% Excluded — 100% Excluded —
8 3 or 4 Yes No 11 70% 11.6 <0.001 80% 6.2 <0.001
% CI: percent cumulative incidence; NRM: nonrelapse mortality; —: nonapplicable, KM: Kaplan-Meier.
patients with severe hyperacute GVHD because of sample
size limitations. These ﬁndings indicate that response is an
independent factor that adds prognostic value beyond the
severity and timing of onset of aGVHD.
4. Discussion
In this study, we evaluated patient, transplant, and aGVHD
factors as predictors of response to standard ﬁrst-line thera-
py. The purpose of this evaluation was to identify a subset
of patients unlikely to receive signiﬁcant beneﬁt from corti-
costeroids and who may beneﬁt from alternative therapeutic
strategies.
None of the patient demographic or transplant charac-
teristics independently predicted response to corticosteroids.
This highlights the need for the development of biomarker
panels in the evaluation of aGVHD using a newer available
technology [14].
Acute GVHD characteristics were the only factors signif-
icantly associated with response to ﬁrst-line therapy, includ-
ing the time of onset of aGVHD and its severity at the ini-
tiation of therapy. Indeed, in this series, only 15% of patients
with severe, hyperacute GVHD had a CR or PR after initial
therapywithcorticosteroids.Patientswithmild-to-moderate
hyperacute aGVHD and severe nonhyperacute GVHD fared
signiﬁcantly better.
We have previously reported that hyperacute GVHD oc-
cursin27%ofgradeII–IVaGVHDpatientsandisassociated
with a lower response rate to therapy and higher NRM [8].
Hyperacute GVHD may be related to damage induced by
the conditioning regimen and its resulting inﬂammatory
cytokine production. This pretransplantation physical dam-
age may be less responsive to corticosteroids than typical
GVHD, prompting a more durable cytokine production and
thus a worse outcome. Severe aGVHD was also signiﬁcantly
associated with a worse response to therapy, consistent with
previous studies [2, 15, 16].
Sex mismatch (female donor to male recipient) was
associated with a decreased response to ﬁrst-line therapy
in severe aGVHD. It was also associated with higher NRM,
independent oftheseverity andtime ofonset ofaGVHD.Sex
mismatchmaycontributetoanincreasedrateofaGVHDdue
to exposure of a parous female donor to non-self-antigens
during pregnancy, thus priming the future donor immune
system to recognize and attack host antigens. It is unclear
why the mismatch would increase the risk for refractory
aGVHD.
Our data showed that day-14 response to ﬁrst-line thera-
py provides additional independent prognostic value beyond
severity and timing of aGVHD. In this study, response was
associated with lower NRM in patients with mild-moder-
ate aGVHD irrespective of the time of onset. It was also asso-
ciatedwithlowerNRMinsevereaGVHDdiagnosedafterday
14 posttransplantation. We could not evaluate its impact in
severe hyperacute GVHD because of sample size limitations.
Recent publications have evaluated the validity of using
response to therapy as primary endpoint in upfront aGVHD
treatment trials [5–7, 14]. Although these reports found
responseatday28tobestatisticallyastrongerpredictor,both
days 14 and 28 were associated with long-term outcomes
and in good agreement. Our data compliment ﬁndings of
these studies indicating that patients who do not respond
to therapy by day 14 are likely to achieve inferior outcomes.
In the current study, we could not compare response on day
14 with response assessed on days 28 or 56 due to the una-
vailability of consistent data on response to therapy at these
time points.
While response on day 28 is a valid endpoint that
facilitates comparison of outcomes across clinical trials in
aGVHD, it does not necessarily dictate the best clinical
practice to improve outcomes in nonresponding patients.
Early identiﬁcation of these patients may allow for aggressive
interventionandperhapsimproveoutcomes.Independentof
the deﬁnition of steroid refractory aGVHD and the timing
for second-line therapy used by each transplant center, re-
thinking the management of these patients prior to day 28
may be warranted.
Inclusion of severity, time of onset, and day 14 response
to ﬁrst-line therapy in scoring criteria may aid in the early
identiﬁcation of patients who are unlikely to receive sig-
niﬁcant beneﬁt from corticosteroids. These patients would,
therefore, be eligible for investigational approaches, includ-
ing customization of therapy and inclusion in clinical studies
which consider more aggressive or innovative strategies
earlier in the disease course [17]. Sex mismatch, the use of
an unrelated donor, and the use of TBI in the conditioning8 Advances in Hematology
regimen independently contribute to the mortality rate as-
sociated with aGVHD. Development of a scoring system that
integrates these factors along with timing and severity of
aGVHD, as well as early response is warranted in a larger
study population.
In conclusion, our results indicate that patients with
severe hyperacute GVHD have inferior response to initial
therapy and higher NRM rates. This patient subgroup is pot-
entially eligible for innovative strategies that ideally could be
implemented upfront, and not after steroid failure has oc-
curred. Our results also suggest that a change in therapy is
warranted by 2 weeks of corticosteroids in patients who have
not developed at least a partial response.
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